SolRUO RETURN
Legal / Document C

Acceptable Use Policy

EFFECTIVE — January 1, 2026VERSION — 1.0JURISDICTION — UNITED STATES

This Acceptable Use Policy applies to every distributor who connects a storefront to SolRUO and every verified research counterparty who transacts through one. Violations are grounds for immediate suspension, termination, and disclosure to the relevant payment processor.

  1. §01

    1. Permitted Activity

    SolRUO supports only the B2B sale of research-use-only compounds to qualified research counterparties — licensed researchers, clinical laboratories, contract research organizations, and credentialed institutional buyers — for in vitro or laboratory research use under 21 CFR §201.128.

  2. §02

    2. Strictly Prohibited Conduct

    • Direct-to-consumer sales of any kind, including via "research" framing that is functionally consumer-facing.
    • Marketing, packaging, labeling, or implying products are intended for human consumption, injection, ingestion, or topical application.
    • Health, therapeutic, anti-aging, performance, recovery, or wellness claims anywhere on the storefront, product pages, metadata, structured data, blog content, reviews, social media, or paid advertising.
    • Bypassing or attempting to bypass the counterparty verification gate, signed attestation, or jurisdiction controls.
    • Removing or weakening the standardized RUO and FDA disclaimer language.
    • Onboarding buyers known or reasonably suspected not to be qualified research counterparties.
    • Selling into jurisdictions identified by SolRUO as restricted or prohibited.
    • Selling controlled substances, scheduled compounds, or any product whose distribution requires a license you do not hold.
    • Operating any compounding-pharmacy activity without proper state and federal licensing.
    • Misrepresenting your business to SolRUO or to your payment processor.
  3. §03

    3. Storefront Content Standards

    Every product page must display: (a) the standardized RUO statement, (b) the standardized FDA non-evaluation disclaimer, (c) a clear "not for human consumption" notice, and (d) a current Certificate of Analysis or link thereto.

    Product titles, descriptions, alt-text, and structured data must not contain consumer or therapeutic framing. The weekly SolRUO compliance scan flags drift; you are responsible for remediation.

  4. §04

    4. Enforcement

    SolRUO may, at its discretion: lock attestation flow, freeze new orders, disable storefront connectivity, notify your processor, terminate your account, and retain a copy of all relevant audit records for the legal retention period.

    SolRUO will give reasonable notice where the circumstances allow it; immediate action is permitted when continued operation would create material processor, regulatory, or third-party risk.

  5. §05

    5. Reporting

    To report suspected violations on any SolRUO-connected storefront, contact trust@solruo.com. Reports may be submitted anonymously.

Questions about this policy? Contact legal@solruo.com. This document does not constitute legal advice.